| Literature DB >> 19539907 |
Abstract
In this prospective longitudinal clinical trial, 87 postmenopausal women receiving for 12 consecutive months a daily dose of 40 mg of a dry extract preparation of Cimicifuga racemosa (Klimadynon) for relief of vasomotor symptoms were followed up by evaluation of total hepatic blood flow, assessed by color Doppler ultrasound, as well as prothrombin time and concentration, serum albumin, bilirubin, gamma-glutamyltransferase, alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase. Because no significant changes in total hepatic blood flow or any of the liver functions tested were reported, we concluded that use of C. racemosa for 1 year by healthy postmenopausal women without evidence of liver disease does not seem to influence the liver.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19539907 DOI: 10.1016/j.fertnstert.2009.05.038
Source DB: PubMed Journal: Fertil Steril ISSN: 0015-0282 Impact factor: 7.329